PYR-41 and Thalidomide Impair Dendritic Cell Cross-Presentation by Inhibiting Myddosome Formation and Attenuating the Endosomal Recruitments of p97 and Sec61 via NF-κB Inactivation
| Autor: | Feng Guang Gao, Di Zhang, Dan Dan Xu, Xiang You, Jie Chen |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
lcsh:Immunologic diseases. Allergy
0301 basic medicine Article Subject Endosome Immunology Endogeny Endosomes medicine.disease_cause Benzoates Mice 03 medical and health sciences chemistry.chemical_compound Cross-Priming medicine Animals Immunology and Allergy Furans Chemistry fungi NF-kappa B Nuclear Proteins Cross-presentation NF-κB Dendritic Cells General Medicine Dendritic cell Thalidomide Cell biology Mice Inbred C57BL 030104 developmental biology Multiprotein Complexes Pyrazoles PYR-41 Female lcsh:RC581-607 Carcinogenesis Immunosuppressive Agents SEC Translocation Channels Research Article Signal Transduction medicine.drug |
| Zdroj: | Journal of Immunology Research Journal of Immunology Research, Vol 2018 (2018) |
| ISSN: | 2314-8861 |
| DOI: | 10.1155/2018/5070573 |
| Popis: | PYR-41 and thalidomide have therapeutic effects on inflammation-associated diseases with side effects such as tumorigenesis. Cross-presentation allows dendritic cells (DC) to present endogenous antigen and induce protective immunity against microbe infection and tumors. But, up to now, the effects of PYR-41 and thalidomide on cross-presentation are still uncertain. In this study, we investigated the effect and mechanism of PYR-41 and thalidomide on DC cross-presentation by observing Myddosome formation, endosomal recruitment of p97 and Sec61, NF-κB activation, and cross-priming ability. We demonstrated that the inhibition of endosomal recruitment of p97 and Sec61, together with attenuated NF-κB activation and Myddosome formation, contributes to PYR-41- and thalidomide-impaired cross-presentation and thereby reverses cross-activation of T cells. These observations suggest that NF-κB signaling and p97 and Sec61 molecules are candidates for dealing with the side effects of PYR-41 and thalidomide. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |